Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma |
| |
| Authors: | Lin-Lin Zheng Chang-Cheng Tao Zong-Gui Tao Kai Zhang An-Ke Wu Jian-Xiong Wu Wei-Qi Rong |
| |
| Affiliation: | Lin-Lin Zheng, Chang-Cheng Tao, Kai Zhang, An-Ke Wu, Jian-Xiong Wu, Wei-Qi Rong, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaZong-Gui Tao, Department of Imaging, Jinan City People's Hospital, Shandong First Medical University, Jinan 271199, Shandong Province, China |
| |
| Abstract: | In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) are important antitumor immunotherapy agents that represent breakthroughs in the treatment of advanced HCC. However, treating advanced HCC is still a great challenge, and the need for new treatments remains urgent. This review briefly summarizes the research progress in the use of PD-1/PD-L1 inhibitors combined with targeted therapy for treating HCC. |
| |
| Keywords: | Programmed cell death 1/programmed cell death ligand 1 inhibitors Targeted therapy Hepatocellular carcinoma Programmed cell death 1 Programmed cell death ligand 1 |
|
| 点击此处可从《World journal of gastrointestinal surgery》浏览原始摘要信息 |
|
